Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy Children
NCT05839301Phase 3Unknown
- Sponsor
- China National Biotec Group
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varicella vaccine live in varicella (VZV) (3 arms), sponsored by China National Biotec Group. Primary endpoint: Geometric mean titers of anti-VZV neutralizing antibodies at 30 days. Status: unknown.
02
Drugs
varicella vaccine live
03
Conditions
varicella (VZV)
Beyond the preview
Go deeper on NCT05839301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839301.